[go: up one dir, main page]

TR199802496T2 - Formulation for the treatment of congestive heart failure. - Google Patents

Formulation for the treatment of congestive heart failure.

Info

Publication number
TR199802496T2
TR199802496T2 TR1998/02496T TR9802496T TR199802496T2 TR 199802496 T2 TR199802496 T2 TR 199802496T2 TR 1998/02496 T TR1998/02496 T TR 1998/02496T TR 9802496 T TR9802496 T TR 9802496T TR 199802496 T2 TR199802496 T2 TR 199802496T2
Authority
TR
Turkey
Prior art keywords
heart failure
congestive heart
formulation
treatment
delayed release
Prior art date
Application number
TR1998/02496T
Other languages
Turkish (tr)
Inventor
L. Mcnay John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199802496T2 publication Critical patent/TR199802496T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus, konjestif kalp yetmezligini, gecikmeli salinimli oral veya implant bir formülasyon ve gecikmeli salinimli formülasyonlar içindeki etkili dozdaThis invention relates to congestive heart failure, an oral or implant formulation with delayed release, and an effective dose of delayed release formulations.

TR1998/02496T 1996-06-06 1997-06-05 Formulation for the treatment of congestive heart failure. TR199802496T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
TR199802496T2 true TR199802496T2 (en) 1999-02-22

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02496T TR199802496T2 (en) 1996-06-06 1997-06-05 Formulation for the treatment of congestive heart failure.

Country Status (17)

Country Link
EP (1) EP0914128A1 (en)
JP (1) JP2000511906A (en)
KR (1) KR20000016406A (en)
CN (1) CN1226166A (en)
AU (1) AU3233197A (en)
BR (1) BR9709546A (en)
CA (1) CA2256720A1 (en)
CZ (1) CZ397698A3 (en)
EA (1) EA199900006A1 (en)
HU (1) HUP0003885A2 (en)
IL (1) IL126966A0 (en)
NO (1) NO985695L (en)
PL (1) PL330637A1 (en)
TR (1) TR199802496T2 (en)
WO (1) WO1997046241A1 (en)
YU (1) YU55998A (en)
ZA (1) ZA974978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (en) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
BR0007894A (en) * 1999-02-01 2001-10-30 Solvay Pharm Gmbh Use of moxonidine for treatment after cardiac infarction
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (en) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 Traffic light shade with reflective layer on the inside

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (en) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermal drug
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
DE4325491A1 (en) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4423177A1 (en) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglycemic drugs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
ZA974978B (en) 1998-12-07
AU3233197A (en) 1998-01-05
PL330637A1 (en) 1999-05-24
CN1226166A (en) 1999-08-18
IL126966A0 (en) 1999-09-22
NO985695D0 (en) 1998-12-04
JP2000511906A (en) 2000-09-12
HUP0003885A2 (en) 2001-04-28
BR9709546A (en) 1999-08-10
WO1997046241A1 (en) 1997-12-11
NO985695L (en) 1999-02-04
EA199900006A1 (en) 1999-06-24
CZ397698A3 (en) 1999-05-12
KR20000016406A (en) 2000-03-25
YU55998A (en) 1999-11-22
CA2256720A1 (en) 1997-12-11
EP0914128A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
DK0760848T3 (en) Lactobacillus strains of human origin, their compositions and their use
TR199802423T2 (en) Concentrated antibody composition.
TR200101481T2 (en) Cancer treatment composition and method using natural herbal essential oils.
TR200101103T2 (en) Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor
YU60900A (en) Novel crystalline forms of an antiviral benzimidazole compound
CY2473B1 (en) New phenanthridines.
TR200100922T2 (en) Application of active substances through the lungs.
BR0314356A (en) Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods using the same
ATE400577T1 (en) ANNATED DIHYDROPYRANS
TR200100054T2 (en) Paroxetine methanesulfonate
TR200100172T2 (en) Biologically strengthened formulations containing eprosartan in oral solid dosage form
TR200102385T2 (en) Self-dissolving N-benzoyl staurosporin compositions.
DK0967987T3 (en) Composition for the treatment of tumors containing shark cartilage extracts and anitneoplastic agents
TR199900951T2 (en) Methods for the prevention of breast cancer.
SE9802937D0 (en) Novel compounds
EE9900450A (en) Tetrahydropyrido compounds, medicament containing them and their use
TR199900505T2 (en)
CA2408541A1 (en) Treating eczema and/or psoriasis
TR199802496T2 (en) Formulation for the treatment of congestive heart failure.
UA32598C2 (en) Method for obtaining of carbamazepin dosage form
TR200002847T2 (en) Form VI 5, 6-dichloro-2- (isopropylamino) -1- (beta-L-ribofuranosyl) -1H-benzimidazole.
TR200002939T2 (en) Paroxetine maleate
MD980129A (en) Antiherpetic remedy
DE50009821D1 (en) Blondiermittel
TR200103169T2 (en) 1,5-Benzodiazepine derivatives